← Back to Search

Antisense Oligonucleotide

LNA043 for Knee Osteoarthritis (ONWARDS Trial)

Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0 to week 104

Summary

This trial tests LNA043 to see if it can help people with knee osteoarthritis by improving cartilage thickness in their knees. It targets patients with worn-down knee cartilage, aiming to reduce pain and improve movement.

Eligible Conditions
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0 to week 104
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0 to week 104 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline in the cartilage thickness of the medial compartment of the knee as assessed by imaging.
Secondary study objectives
Assessing percentage of participants with adverse events and serious adverse events
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index function scale. The scale (17 questions) ranges from 0 to 170. Higher scores indicates a worse outcome.
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index pain scale. The scale (5 questions) ranges from 0 to 50. Higher score indicates a worse outcome.
+5 more

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: LNA043 Dosing Regimen DExperimental Treatment1 Intervention
LNA043 injection to the knee with dosing regimen D
Group II: LNA043 Dosing Regimen CExperimental Treatment1 Intervention
LNA043 injection to the knee with dosing regimen C
Group III: LNA043 Dosing Regimen BExperimental Treatment1 Intervention
LNA04 injection to the knee with dosing regimen B
Group IV: LNA043 Dosing Regimen AExperimental Treatment1 Intervention
LNA043 injection to the knee with dosing regimen A
Group V: PlaceboPlacebo Group1 Intervention
Injection to the knee

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,911 Previous Clinical Trials
4,250,096 Total Patients Enrolled
12 Trials studying Osteoarthritis
1,992 Patients Enrolled for Osteoarthritis

Media Library

LNA043 (Antisense Oligonucleotide) Clinical Trial Eligibility Overview. Trial Name: NCT04864392 — Phase 2
Osteoarthritis Research Study Groups: Placebo, LNA043 Dosing Regimen A, LNA043 Dosing Regimen B, LNA043 Dosing Regimen C, LNA043 Dosing Regimen D
Osteoarthritis Clinical Trial 2023: LNA043 Highlights & Side Effects. Trial Name: NCT04864392 — Phase 2
LNA043 (Antisense Oligonucleotide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04864392 — Phase 2
Osteoarthritis Patient Testimony for trial: Trial Name: NCT04864392 — Phase 2
~132 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top